Saluda Medical Q1 FY27 slides: patient growth surges despite revenue miss

Saluda Medical reported a 55% year-over-year increase in US patient implants to 838 patients in Q1 FY27, despite revenue falling short of expectations with total revenue at $23.1 million. The company reaffirmed its full-year guidance while acknowledging a cash runway extending only to approximately June 2027. Saluda's Q1 FY27 results demonstrated accelerating market penetration across key operational metrics, with US patient implant growth significantly outpacing revenue growth.

The company's Evoke® System, which uses closed-loop neural-sensing technology, addresses structural problems in the spinal cord stimulation market by providing personalized therapy and maintaining target activation levels for individual patients.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.